Virpax Pharmaceuticals (VRPX) News Today $0.01 0.00 (0.00%) As of 09/2/2025 11:31 AM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRPX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Virpax Pharmaceuticals stock plummets on Nasdaq delisting newsApril 3, 2025 | investing.comVirpax Pharmaceuticals Inc trading halted, news pendingMarch 21, 2025 | markets.businessinsider.comVirpax reports positive results in Probudur dog studyMarch 20, 2025 | investing.comVirpax receives positive Probudur results for dose range studyMarch 20, 2025 | markets.businessinsider.comVirpax Pharmaceuticals announces 1-for-25 reverse stock splitMarch 20, 2025 | markets.businessinsider.comVirpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in INDMarch 18, 2025 | finance.yahoo.comVirpax Pharmaceuticals files to sell common stock and warrants, no amount givenMarch 18, 2025 | markets.businessinsider.comVirpax Pharmaceuticals Explores Intranasal mRNA Vaccine Delivery Using METMarch 11, 2025 | msn.comVirpax Pharmaceuticals to Present NES100 Toxicity Study at Major Toxicology ConferenceMarch 11, 2025 | msn.comVirpax Looking to Use MET to Develop Intranasal COVID VaccineMarch 7, 2025 | businesswire.comAnalysts Conflicted on These Healthcare Names: Clearside Biomedical (CLSD) and Virpax Pharmaceuticals (VRPX)March 6, 2025 | markets.businessinsider.comVirpax’s NES100 to be Presented at The Society of Toxicology by NCATSMarch 5, 2025 | finance.yahoo.comVirpax Pharmaceuticals Applauds Successful Trial of Molecular Envelope TechnologyMarch 3, 2025 | msn.comVirpax lauds Nanomerics’ MET study with no severe side effectsMarch 1, 2025 | investing.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | finance.yahoo.comVirpax Reports Positive Results in Human Study for its Molecular Envelope TechnologyFebruary 27, 2025 | businesswire.comVirpax Pharmaceuticals confirms results with U.S. Army with ProbudurFebruary 13, 2025 | markets.businessinsider.comVirpax reports positive study results for pain management drugFebruary 13, 2025 | msn.comVirpax Pharmaceuticals appoints new independent directorFebruary 6, 2025 | msn.comVirpax Pharmaceuticals director resigns due to complianceFebruary 5, 2025 | msn.comVirpax's Matthew Barnes to Present at Outsourcing in Clinical Trials ConferenceJanuary 31, 2025 | businesswire.comSpartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals’ $6 Million Follow-On OfferingJanuary 30, 2025 | markets.businessinsider.comSpartan Capital Securities Serves as Sole Placement Agent in Virpax Pharmaceuticals' $6 Million Follow-On OfferingJanuary 30, 2025 | globenewswire.comVirpax Pharmaceuticals, Inc. Announces Closing of $6.0 Million Public Offering of Common Stock and Pre-Funded WarrantsJanuary 30, 2025 | businesswire.comVirpax Pharmaceuticals, Inc. Announces Pricing of $6 Million Public Offering of Common Stock and Pre-Funded WarrantsJanuary 28, 2025 | finance.yahoo.comVirpax Pharmaceuticals sets public offering at $0.20 per shareJanuary 28, 2025 | msn.comVirpax Pharmaceuticals stock hits 52-week low at $0.29January 21, 2025 | msn.comVirpax Pharmaceuticals Inc Ordinary SharesJanuary 7, 2025 | morningstar.comMVirpax Updates Executive Agreements for Legal ComplianceDecember 30, 2024 | markets.businessinsider.comVirpax Pharmaceuticals Extends Collaboration with NIH Center for Pain Management InnovationNovember 27, 2024 | msn.comVirpax Pharmaceuticals Announces Positive Results in Study for Long-Lasting Pain Relief FormulationNovember 27, 2024 | msn.comVirpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur(TM)November 24, 2024 | stockhouse.comVirpax Pharmaceuticals extends NIH pain management researchNovember 23, 2024 | investing.comVirpax Pharmaceuticals announces results from Probudur minipig DRF studyNovember 23, 2024 | markets.businessinsider.comVirpax Pharmaceuticals Strengthens Leadership and Expands CollaborationsNovember 22, 2024 | tipranks.comVirpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™November 22, 2024 | finance.yahoo.comWhy Is Virpax Pharmaceuticals Stock Gaining On Friday?November 22, 2024 | benzinga.comVirpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudurâ„¢November 22, 2024 | businesswire.comVirpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain AlternativeNovember 21, 2024 | businesswire.comSpartan Capital Securities, LLC Serves as Sole Placement Agent in Virpax Pharmaceuticals, Inc.'s $5.0 Million Public OfferingNovember 18, 2024 | globenewswire.comVirpax Pharmaceuticals Announces $5M Public OfferingNovember 16, 2024 | markets.businessinsider.comVirpax Pharmaceuticals, Inc. Announces Closing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsNovember 15, 2024 | businesswire.comVirpax Pharmaceuticals, Inc. Announces Pricing of $5.0 Million Public Offering of Common Stock and Pre-Funded WarrantsNovember 13, 2024 | finance.yahoo.comAdial Pharmaceuticals appoints Shah as Chief Financial OfficerNovember 6, 2024 | markets.businessinsider.comVirpax Pharmaceuticals (NASDAQ:VRPX) Stock, Short Interest ReportOctober 2, 2024 | benzinga.comVirpax Pharmaceuticals (NASDAQ:VRPX) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comVirpax Pharmaceuticals’ Promising Outlook: Buy Rating Justified by Strategic Financial Management and Innovative Pain Management PipelineAugust 16, 2024 | markets.businessinsider.comVirpax Pharmaceuticals to Present at Sidoti August Virtual Investor ConferenceAugust 13, 2024 | msn.comVirpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent DevelopmentsAugust 13, 2024 | finance.yahoo.comVRPX Stock Earnings: Virpax Pharmaceuticals Reported Results for Q2 2024August 12, 2024 | investorplace.com Get Virpax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VRPX Media Mentions By Week VRPX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRPX News Sentiment▼0.000.70▲Average Medical News Sentiment VRPX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRPX Articles This Week▼01▲VRPX Articles Average Week Get the Latest News and Ratings for VRPX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Virpax Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SYRS News SMFL News AIMDW News BCTXW News GDTC News ENGNW News FBIOP News GLPG News GOVXW News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRPX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virpax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Virpax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
